KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related macular degeneration.
According to Abbey, the trial achieved its primary endpoint of noninferiority in change in best corrected visual acuity with EYP-1901 (vorolanib intravitreal insert, EyePoint Pharmaceuticals) compared with aflibercept between weeks 28 and 32. Patients who received EYP-1901 also required significantly fewer treatments, demonstrating a positive reduction in